Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Connie Welch’s interview of John M, who was successfully treated and cured from hepatitis C in 2014 with Harvoni.
Important information If you are Black and your medical provider prescribes 8 weeks of hepatitis C treatment using Harvoni.
German study shows high hepatitis C virus cure rates after eight weeks of Harvoni (ledipasvir/sofosbuvir) treatment.
A small trial of those very recently infected with genotype 1 of the virus saw a 100 percent success rate.
Real-world results of eight weeks of the hepatitis C virus treatment Harvoni (ledipasvir/sofosbuvir) are excellent.
What new therapies are the major players in hepatitis C pharmaceuticals developing?
The US will likely bear the brunt of cost of treating hepatitis C by 2020, after which point the financial burden will shrink considerably.
Elizabeth Faraone, now cured of hepatitis C, discusses treatment and the power of advocacy
Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
8 weeks of Harvoni (ledipasvir/sofosbuvir) and vedroprevir boasted a near-perfect cure rate among those with genotype 1 and advanced liver dis...
An eight-week treatment of Gilead Sciences hepatitis C treatment Harvoni has demonstrated excellent results in a real-world trial.
Individuals who experience a rapid undetectable viral load on a triple regimen of hepatitis C drugs may only need three weeks of treatment.
The FDA has approved new indications for Gilead’s Harvoni: to treat hepatitis C in those with genotypes 4, 5 and 6 of the virus and in...
Hepatitis C regimens containing sofosbuvir, including ledipasvir/sofosbuvir, may cause an abnormally slow heart rate in rare cases.
Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of hep C
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.